Stock INTS INTENSITY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
3.75 USD -0.53% Intraday chart for Intensity Therapeutics, Inc. -2.60% -56.24%
Apr. 19 Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors CI
Mar. 14 Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intensity Therapeutics : Failure to Satisfy Listing Rule - Form 8-K
PU
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
PR
Portage biotech completes monetization of intensity therapeutics shares
AQ
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
AQ
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
PR
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
PR
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
PR
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
PR
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
AQ
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
PR
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
AQ
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
PR
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
PR
Abstract 1574238: Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety and Immune Activation in Adults with Refractory Sarcomas (NCT 03058289)
PU
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
PR
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma
PR
Intensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PR
Intensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
AQ
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
PR
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INTS Stock
  4. News Intensity Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW